Trump's drug price initiatives have not benefited certain voter groups

Meaningful drug price relief legislation or enforcement would likely ease margin pressure on insurers and PBMs while creating near-term headwinds for pharma revenues, though the net effect on healthcare sector valuations would depend on the mechanism and scope of any intervention.

Continued stagnation in drug price policy would leave pharmaceutical pricing power largely intact, supporting margins in that sector while consumer healthcare cost inflation persists as a political liability without material market repricing.

Escalation into aggressive price controls, regulatory clawbacks, or high-profile enforcement actions against pharma companies could create volatility in healthcare equities and shift investor risk premiums across the sector depending on the specificity and retroactivity of any measures.